Increased Frequencies of Switched Memory B Cells and Plasmablasts in Peripheral Blood from Patients with ANCA-Associated Vasculitis
Table 1
Patient characteristics and demographics.
GPA ()
MPA ()
EGPA ()
Age, years, median (IQR)
67.0 (55.0-73.8)
73.0 (63.0-82.0)
71.0 (56.0-76.0)
Female/male, (%)
26 (41)/38 (59)
19 (54)/16 (46)
5 (71)/2 (29)
Age at diagnosis, years, median (IQR)
50.5 (37.3-66.0)
68.0 (60.0-75.0)
66.0 (38.0-71.0)
Disease duration, years, median (IQR)
6.74 (3.59-17.8)
2.21 (0.447-9.95)
7.91 (4.82-18.0)
ANCA specificity, (%)
PR3
45 (70)
2 (6)
0 (0)
MPO
17 (27)
30 (86)
3 (43)
PR3 and MPO
0 (0)
1 (3)
0 (0)
No ANCA
1 (1.5)
1 (3)
3 (43)
Data not available
1 (1.5)
1 (3)
1 (14)
Disease activity
Active disease, (%)
14 (22)
9 (26)
1 (14)
BVAS3, median (range)
6 (2-26)
14 (5-21)
4
Remission, (%)
50 (78)
26 (74)
6 (86)
Tendency to relapse, (%)
Yes
29 (45)
8 (23)
1 (14)
Time since onset of the latest relapse, months, median (IQR)a
66.5 (24.5-178)
8.30 (4.73-26.8)
NA
No
18 (28)
13 (37)
5 (71)
Not applicable
17 (27)
14 (40)
1 (14)
WBC, 109/L, median (IQR)b
6.55 (5.10-8.45)
7.70 (5.65-9.40)
7.40 (5.48-10.1)
P-CRP, mg/L, median (IQR)c
2.25 (1.10-4.55)
6.70 (2.00-14.5)
0.00 (0.00-3.23)
P-creatinine, μmol/L, median (IQR)d
102 (80.0-136)
137 (101-193)
84.5 (62.8-108)
eGFR, mL/min/1.73 m2, median (IOR)
58.0 (40.0-80.0)
39.0 (21.0-51.0)
69.0 (52.8-88.0)
Medication, (%), dose, median (IQR)
Prednisolone, mg/day
30 (47) 6.88 (5.00-13.1)
22 (63) 10.0 (8.75-31.3)
4 (57) 5.00 (2.13-16.9)
Azathioprine, mg/day
16 (25) 100 (75.0-144)
13 (37) 100 (75.0-100)
4 (57) 125 (100-188)
Methotrexate, mg/week
9 (14) 25.0 (17.5-25.0)
0 (0)
0 (0)
Mycophenolate mofetil, mg/day
6 (9) 2000 (1313-2125)
0 (0)
0 (0)
Cyclophosphamide
4 (6)
7 (20)
0 (0)
No medication
18 (28)
6 (17)
2 (29)
GPA: granulomatosis with polyangiitis; MPA: microscopic polyangiitis; EGPA: eosinophilic granulomatosis with polyangiitis; IQR: interquartile range; ANCA: antineutrophil cytoplasmic autoantibodies; PR3: proteinase 3; MPO: myeloperoxidase; BVAS3: Birmingham Vasculitis Activity Score version 3; NA: not applicable; WBC: white blood cell; CRP: C-reactive protein; eGFR: estimated glomerular filtration rate. aFor those in remission at the time of sampling. (GPA), (MPA). bReference range 3.5-8.8 109/L. cReference mg/L. dReference range 60-105 μmol/L (male), 45-90 μmol/L (female). For BVAS3, WBC, P-CRP, P-creatinine, and eGFR, the cohort sizes were (GPA), (MPA), and (EGPA).
